News and Trends 9 Aug 2016
Ablynx’ Best-In-Class Antibody might not be that ‘Compelling’ to Abbvie
Ablynx has disclosed ‘compelling’ results for its Phase IIb trial in rheumatoid arthritis. But it might have a hard time compelling AbbVie to pay €68M to continue the candidate’s development, as the grass is not as green as it seems… Ablynx‘s impressive list of big Pharma collaborations could soon need an update, as its $840 partnership with […]